Photobiomodulation Therapy- PBMT, was previously known as Low Level Laser Therapy, or LLLT.
THOR Photomedicine is the manufacturer of the photobiomodulation devices used at Borealis Photobiomodulation Light Therapy. THOR has a long history with over 3,000 customers in pioneering clinics and hospitals in more than 70 countries.
THOR is the only PBMT company with FDA, CE, TGA, Health Canada and NATO clearance.
Enstein first proposed the phenomenon of stimulated emission
Theodore "Ted" Maiman invented, built and patented the world's first laser
Prof. Mester- Budapest- discovers laser biostimulation
UK Physios first use low power laser for sports injuries treatment
James Carroll raised British Pounds for laser research at Guys Hospital London
NASA conducted LED therapy wound healing study for space
US Navy nerve regeneration research with THOR lasers
First FDA clearance for THOR
Spinal chord regeneration
LLLT published in Nature and Pain
WHO Bone & Joint Task Force recommend on neck pain (Spine)
Lancet systematic review LLLT for neck pain
APTA recommends LLLT for Achillles Tendonopathies
Intl Assoc for the Study of Pain, "strong evidence" for Myofiscial Pain Syndrome
BJSM "strong evidence" for LLLT on frozen shoulder
BMJ Tennis Elbow "Likely to be beneficial for short-term pain relief & improvement of function"
ESMO guideline revisions suggest the use of LLLT to reduce the incidence and severity of Oral Mucositis
BJSM "moderate evidence was found in favour of laser therapy over exercises" for Tennis Elbow
JAppl Oral Science TMD "it seems clear that the use of laser brings benefits when properly applied and administered"
MASCC guideline recommend the use of LLLT to reduce the incidence and severity of Oral Mucositis
J Cancer Survivorship LLLT confers clinically meaningful reductions in arm volume and pain in women with Lymphoedema
BMJ Chronic Non specific Low Back PAin Systematic Review
The British Medical Journal (BMJ) LLLT for chronic non-specific low back pain: a systematic review and meta-analysis of randomised controlled trials found "moderate quality of evidence" and "clinically important benefits" in the short term. (2016)